ES2187522T3 - Inhibicion de la produccion de oxido nitrico por el acido retinoico. - Google Patents

Inhibicion de la produccion de oxido nitrico por el acido retinoico.

Info

Publication number
ES2187522T3
ES2187522T3 ES94917915T ES94917915T ES2187522T3 ES 2187522 T3 ES2187522 T3 ES 2187522T3 ES 94917915 T ES94917915 T ES 94917915T ES 94917915 T ES94917915 T ES 94917915T ES 2187522 T3 ES2187522 T3 ES 2187522T3
Authority
ES
Spain
Prior art keywords
retinoic acid
nitric oxide
inhibition
oxide production
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94917915T
Other languages
English (en)
Inventor
Bharat B Aggarwal
Kapil Mehta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of ES2187522T3 publication Critical patent/ES2187522T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN NUEVO METODO PARA INHIBIR LA PRODUCCION DE DOS MEDIADORES IMPORTANTES DE LA FUNCION CELULAR, EL FACTOR NECROTICO DE TUMORES Y EL OXIDO NITRICO, Y TRATAMIENTO DE UN ESTADO PATOFISIOLOGICO CARACTERIZADO POR UNA PRODUCCION O NIVEL INDESEABLES DEL FACTOR NECROTICO DE TUMORES O DE ACIDO NITRICO. EN LOS METODOS DE LA PRESENTE INVENCION SE UTILIZAN COMPUESTO DE ACIDO RETINOICO. EL ACIDO RETINOICO PREFERENTES ES EL ACIDO AL-TRANS-RETINOICO.
ES94917915T 1993-05-17 1994-05-05 Inhibicion de la produccion de oxido nitrico por el acido retinoico. Expired - Lifetime ES2187522T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/061,471 US5457129A (en) 1993-05-17 1993-05-17 Inhibition of nitric oxide production by retinoic acid

Publications (1)

Publication Number Publication Date
ES2187522T3 true ES2187522T3 (es) 2003-06-16

Family

ID=22036008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94917915T Expired - Lifetime ES2187522T3 (es) 1993-05-17 1994-05-05 Inhibicion de la produccion de oxido nitrico por el acido retinoico.

Country Status (17)

Country Link
US (2) US5457129A (es)
EP (2) EP1243264A3 (es)
JP (2) JPH08510727A (es)
KR (1) KR100345255B1 (es)
AT (1) ATE228363T1 (es)
AU (1) AU697072B2 (es)
CA (1) CA2162990A1 (es)
DE (1) DE69431801T2 (es)
DK (1) DK0708648T3 (es)
ES (1) ES2187522T3 (es)
IL (1) IL109458A (es)
NZ (1) NZ267220A (es)
PT (1) PT708648E (es)
SA (1) SA94150042B1 (es)
TW (1) TW261529B (es)
WO (1) WO1994026277A1 (es)
ZA (1) ZA943320B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
FR2735371B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes antagonistes des recepteurs rars
FR2767058B1 (fr) * 1997-08-05 2000-05-05 Centre Nat Rech Scient Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
CA2303418A1 (en) * 1997-09-02 1999-03-11 Sumitomo Pharmaceuticals Company, Limited Dna participating in regulation of expression o pebp2 .alpha.a gene, and use thereof
US6596500B1 (en) * 1998-12-08 2003-07-22 The General Hospital Corporation Binding of retinoids to M6P/IGF-II receptor
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
AU7895000A (en) * 1999-10-19 2001-04-30 Kevin C Kain Products and methods for activating ppargamma-rxr and up-regulating monocyte/macrophage cd36 for the treatment of malaria
WO2002058586A2 (en) * 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
US7071228B2 (en) * 2002-10-23 2006-07-04 Parks L Dean Method of treating musculoskeletal and connective tissue inflammations
US20060183102A1 (en) * 2005-02-14 2006-08-17 Young Henry E Serum-free reagents for the isolation, cultivation, and cryopreservation of postnatal pluripotent epiblast-like stem cells
US20110081410A1 (en) * 2005-06-28 2011-04-07 St. Marianna University, School Ofmedicine Therapeutic agent for local inflammation
WO2007104030A1 (en) * 2006-03-08 2007-09-13 Kinemed, Inc. Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200647A (en) * 1977-12-21 1980-04-29 Hoffmann-La Roche Inc. Vitamin A compositions to treat rheumatic disease
EP0071357B1 (en) * 1981-07-14 1985-01-02 Efamol Limited Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US5264578A (en) * 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
EP0397774A1 (en) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
US5157046A (en) * 1988-11-29 1992-10-20 Janssen Pharmaceutica N.V. Method of treating epithelial disorders
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
JPH051100A (ja) * 1990-07-11 1993-01-08 Teijin Ltd 腫瘍壊死因子活性抑制物質及びその製造方法
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ES2145744T5 (es) * 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
EP0593585B1 (en) * 1991-07-05 2002-05-02 Peptech Limited Peptide which abrogates tnf and lps toxicity
WO1993016067A1 (en) * 1992-02-11 1993-08-19 Allergan, Inc. Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity

Also Published As

Publication number Publication date
ATE228363T1 (de) 2002-12-15
IL109458A0 (en) 1994-07-31
CA2162990A1 (en) 1994-11-24
SA94150042B1 (ar) 2006-06-17
EP1243264A2 (en) 2002-09-25
NZ267220A (en) 2000-08-25
US5457129A (en) 1995-10-10
DE69431801D1 (de) 2003-01-09
ZA943320B (en) 1995-11-16
AU6944194A (en) 1994-12-12
KR960702311A (ko) 1996-04-27
KR100345255B1 (ko) 2002-11-30
PT708648E (pt) 2003-04-30
JPH08510727A (ja) 1996-11-12
TW261529B (es) 1995-11-01
WO1994026277A1 (en) 1994-11-24
IL109458A (en) 2001-11-25
DK0708648T3 (da) 2003-03-03
US5658949A (en) 1997-08-19
EP0708648B1 (en) 2002-11-27
JP2005263808A (ja) 2005-09-29
EP1243264A3 (en) 2002-11-06
EP0708648A4 (en) 1998-01-14
EP0708648A1 (en) 1996-05-01
DE69431801T2 (de) 2003-09-11
AU697072B2 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
ES2187522T3 (es) Inhibicion de la produccion de oxido nitrico por el acido retinoico.
AR241226A1 (es) 3-(2,2-difluorbenzodioxol-4-il)-4-cianopirrol procedimiento para su preparacion, intermediario y composion microbicida que contiene dicho compuesto.
EA200100772A1 (ru) Бензогетероциклы и их применение в качестве мек ингибиторов
EA200401579A1 (ru) Замещенные соединения метациклина (варианты), фармацевтическая композиция (варианты) и способ лечения чувствительного к тетрациклину состояния млекопитающего (варианты)
EA200300030A1 (ru) Производные гексагидро-7-1h-азепин-2-илкапроевой кислоты в качестве ингибиторов индуцибельной синтазы оксида азота
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
EA200201054A1 (ru) Галогенированные производные 2-амино-5,6-гептеновой кислоты в качестве ингибиторов синтазы оксида азота
TR200103493T2 (tr) Metaloproteaz önleyicileri
SE0301886D0 (sv) New use V
DE60328909D1 (de) Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
EA200300377A1 (ru) Производные 2-амино-2-алкил-5-гептеновой и -гептиновой кислот, которые могут быть использованы в качестве ингибиторов синтетазы оксида азота
DK0666843T3 (da) Sulfonylalkanoylaminohydroxyethylaminosulfaminsyrer, der kan anvendes som inhibitorer af retrovirale proteaser
DE60017878D1 (de) Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind
ES8700254A1 (es) Un procedimiento para la preparacion de aminoalcoxibenzopiranonas.
ES8306751A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroariltiazoles.
AR118059A1 (es) Tratamiento de formaciones subterráneas
AU2003283300A1 (en) Coating composition, particularly for glass surfaces, and methods for the production and use thereof
ES8304070A1 (es) "procedimiento para la preparacion de nuevas amidas de acidos carboxilicos".
ECSP056059A (es) Un proceso para la preparación de oxi-(1h)-quinolin-2-onas 5-(haloacetil)-8-sustituidas
ES2155091T3 (es) Procedimiento para la produccion de inhibidores de la proteasa del vih.
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
DK0633924T3 (da) Anvendelse af rengøringsmidler til hårde overflader, især glas
ES2183940T3 (es) Inhibidores de proteasas de parasitos metazoarios.
ES2191683T3 (es) Procedimiento para preparar inhibidores de la proteasa del vih.
EA200300567A1 (ru) Лечение состояний тревоги